Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A critical appraisal of the STEP-5 semaglutide trial, covering enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest concerns, and what peer commentary revealed about the 104-week weight-loss data.
Read clinical reviewA clinical-research deep dive into the STEP-5 trial design, randomization, estimand framework, and statistical choices that shaped the 104-week semaglutide weight-loss result.
Read clinical reviewA deep-dive into the economic modeling, payer-coverage implications, and individual-patient value calculations derived from the STEP-5 semaglutide 2.4 mg trial, including cost-per-QALY estimates, list-price vs net-price realities, and what two years of durable weight loss actually costs per kilogram lost.
Read clinical reviewA deep dive into the STEP-5 trial results for semaglutide 2.4 mg, covering primary and secondary endpoints, effect sizes, confidence intervals, response distribution, and the 104-week time course of weight loss.
Read clinical reviewA deep-dive into the STEP-5 randomized controlled trial examining semaglutide 2.4 mg for long-term weight management over 104 weeks, including methodology, results, limitations, and clinical implications.
Read clinical reviewA deep-dive into the STEP-5 trial's 104-week semaglutide data and what it means for real-world prescribing, guideline updates, and long-term obesity pharmacotherapy.
Read clinical review